NEWARK, Calif., Feb. 16, 2021 /PRNewswire/ -- Protagonist
Therapeutics, Inc. (NASDAQ: PTGX) today announced that Dinesh V. Patel, Ph.D., President and Chief
Executive Officer, will participate in a fireside chat at SVB
Leerink Virtual 10th Annual Global Healthcare Conference taking
place February 22 to February 26,
2021.
Fireside chat details:
Date: Wednesday, February 24, 2021
Time: 10:40 a.m. EST
A live and archived webcast of the event will be available at
https://wsw.com/webcast/svbleerink47/ptgx/2693120 and on the
Investors section of the Protagonist Therapeutics website at
http://investors.protagonist-inc.com/.
About Protagonist Therapeutics, Inc.
Protagonist Therapeutics is a clinical stage biopharmaceutical
company with multiple peptide-based new chemical entities in
different stages of development. PTG-300 is an injectable hepcidin
mimetic in a Phase 2 proof-of-concept clinical trial for
polycythemia vera, and a separate Phase 2 clinical study for
hereditary hemochromatosis. PTG-200 is an orally delivered,
gut-restricted, interleukin-23 receptor specific antagonist peptide
in a Phase 2 clinical trial for Crohn's disease. Two additional
oral peptide interleukin-23 receptor antagonist candidates are in
development: PN-235, in a Phase 1 study, and PN-232, in the late
preclinical stage. PN-943 is an orally delivered, gut-restricted
alpha-4-beta-7 integrin specific antagonist peptide in a Phase 2
study for the potential treatment of inflammatory bowel disease,
with ulcerative colitis as the initial targeted indication. The
Company utilizes a proprietary technology platform to discover and
develop novel peptide-based therapeutics to address significant
unmet medical needs and transform existing treatment paradigms.
Protagonist is headquartered in Newark, California. For further information,
please visit http://www.protagonist-inc.com.
View original content to download
multimedia:http://www.prnewswire.com/news-releases/protagonist-therapeutics-to-participate-in-the-svb-leerink-virtual-10th-annual-global-healthcare-conference-301227755.html
SOURCE Protagonist Therapeutics, Inc.